Depiction of Episode one: The contribution of good corporate governance to the market valuation of European companies

Episode one: The contribution of good corporate governance to the market valuation of European companies



Brussels was the ideal setting for our most recent two-part Agenda podcast, where the European Contact Group brought together different stakeholders to discuss the results of Oxera’s report, An analysis of the EU governance framework for corporate reporting.

In episode one of the podcast, we present and discuss the conclusions of the report, which were debated among academics, policymakers, and business people.

Joining Russell Goldsmith on the podcast is Dr Luis Correia da Silva, Oxera Chair and Partner, who presented alongside Professor Ryan Williams, Université Paris-Dauphine. Andrew Hobbs, EY EMEIA Public Policy Leader, chaired the panel which includes Karel Lannoo, Chief Executive Officer, Centre for European Policy Studies, Professor Nicole Ratzinger-Sakel, University of Hamburg, Chiara Mosca, Commissioner, Italian Securities and Financial Markets Authority, and Gabriela Dias, Chair at the International Ethics Board for Accountants. 

Related

< 1 minute read
Depiction of AI and fairness: who captures the gains and who is bearing the costs?

AI and fairness: who captures the gains and who is bearing the costs?

Who benefits from AI’s economic value? Much of the discussion around AI focuses on the tasks the technology is replacing. But arguably just as important are the economic questions about competitive advantage: who is capturing the gains, and how widely are they being shared? In this episode of… Read More

Articles
6 minute read
Depiction of From uncertainty to causation: a valuation perspective on life sciences disputes

From uncertainty to causation: a valuation perspective on life sciences disputes

How do you value a product that may never reach the market? How do you distinguish commercial opportunity from scientific possibility? How do you assess loss in markets shaped by regulation, reimbursement and patient behaviour? These are just some of the valuation questions that arise in life sciences… Read More

Back to top